Maze Therapeutics, Inc. (MAZE)
$27.97-$0.63 (-2.20%) Today
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 21 | 171,607 | $4.73M |
| Grant or award | 8 | 180,000 | |
| Option exercise | 12 | 136,208 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
62 Form 4 filings on record, the earliest from Aug 17, 2025, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Misbah Tahir - Officer | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Misbah Tahir - Officer | Grant or award | Restricted Stock Units | 20,000 | $0.00 | - | |
| Phillips Courtney - Officer | Grant or award | Stock Option (Right to Buy) | 32,000 | $0.00 | - | |
| Phillips Courtney - Officer | Grant or award | Restricted Stock Units | 16,000 | $0.00 | - | |
| Atul Dandekar - Officer | Option exercise | Common Stock | 7,500 | $10.42 | $78K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 3,739 | $45.13 | $169K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 3,761 | $45.72 | $172K | |
| Atul Dandekar - Officer | Option exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| Atul Dandekar - Officer | Grant or award | Stock Option (Right to Buy) | 38,000 | $0.00 | - | |
| Atul Dandekar - Officer | Grant or award | Restricted Stock Units | 19,000 | $0.00 | - | |
| Harold Bernstein - Officer | Grant or award | Stock Option (Right to Buy) | 48,000 | $0.00 | - | |
| Harold Bernstein - Officer | Grant or award | Restricted Stock Units | 24,000 | $0.00 | - | |
| Amy Bachrodt - Officer | Option exercise | Common Stock | 5,000 | $10.42 | $52K | |
| Amy Bachrodt - Officer | Grant or award | Stock Option (Right to Buy) | 32,000 | $0.00 | - | |
| Amy Bachrodt - Officer | Open-market sale | Common Stock | 1,300 | $44.44 | $58K | |
| Amy Bachrodt - Officer | Open-market sale | Common Stock | 3,700 | $45.47 | $168K | |
| Amy Bachrodt - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| Amy Bachrodt - Officer | Grant or award | Restricted Stock Units | 16,000 | $0.00 | - | |
| Jason V. Coloma - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | $0.00 | - | |
| Jason V. Coloma - Officer | Grant or award | Restricted Stock Units | 75,000 | $0.00 | - | |
| Harold Bernstein - Officer | Option exercise | Common Stock | 15,000 | $10.42 | $156K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 600 | $44.21 | $27K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 8,364 | $45.89 | $384K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 5,936 | $46.37 | $275K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 100 | $47.23 | $5K | |
| Harold Bernstein - Officer | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Amy Bachrodt - Officer | Option exercise | Common Stock | 4,844 | $10.42 | $50K | |
| Amy Bachrodt - Officer | Option exercise | Common Stock | 156 | $10.42 | $2K | |
| Amy Bachrodt - Officer | Open-market sale | Common Stock | 200 | $44.15 | $9K | |
| Amy Bachrodt - Officer | Open-market sale | Common Stock | 4,064 | $46.03 | $187K | |
| Amy Bachrodt - Officer | Open-market sale | Common Stock | 736 | $46.63 | $34K | |
| Amy Bachrodt - Officer | Option exercise | Stock Option (Right to Buy) | 4,844 | $0.00 | - | |
| Amy Bachrodt - Officer | Option exercise | Stock Option (Right to Buy) | 156 | $0.00 | - | |
| Atul Dandekar - Officer | Option exercise | Common Stock | 7,500 | $10.42 | $78K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 1,200 | $43.18 | $52K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 3,500 | $44.04 | $154K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 2,800 | $45.01 | $126K | |
| Atul Dandekar - Officer | Option exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| Amy Bachrodt - Officer | Option exercise | Common Stock | 2,497 | $10.42 | $26K | |
| Amy Bachrodt - Officer | Option exercise | Common Stock | 2,503 | $10.42 | $26K | |
| Amy Bachrodt - Officer | Open-market sale | Common Stock | 5,000 | $45.52 | $228K | |
| Amy Bachrodt - Officer | Option exercise | Stock Option (Right to Buy) | 2,497 | $0.00 | - | |
| Amy Bachrodt - Officer | Option exercise | Stock Option (Right to Buy) | 2,503 | $0.00 | - | |
| Harold Bernstein - Officer | Option exercise | Common Stock | 25,156 | $10.42 | $262K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 25,156 | $40.20 | $1.01M | |
| Harold Bernstein - Officer | Option exercise | Stock Option (Right to Buy) | 25,156 | $0.00 | - | |
| Catherine A. Sohn | Option exercise | Common Stock | 2,493 | $10.42 | $26K | |
| Catherine A. Sohn | Option exercise | Common Stock | 20,744 | $10.42 | $216K | |
| Catherine A. Sohn | Option exercise | Common Stock | 2,895 | $10.42 | $30K | |
| Catherine A. Sohn | Option exercise | Common Stock | 3,281 | $10.42 | $34K | |
| Catherine A. Sohn | Open-market sale | Common Stock | 2,493 | $38.62 | $96K | |
| Catherine A. Sohn | Open-market sale | Common Stock | 26,920 | $39.11 | $1.05M | |
| Catherine A. Sohn | Option exercise | Stock Option (Right to Buy) | 2,493 | $0.00 | - | |
| Catherine A. Sohn | Option exercise | Stock Option (Right to Buy) | 20,744 | $0.00 | - | |
| Catherine A. Sohn | Option exercise | Stock Option (Right to Buy) | 2,895 | $0.00 | - | |
| Catherine A. Sohn | Option exercise | Stock Option (Right to Buy) | 3,281 | $0.00 | - | |
| Charles J. Homcy | Other | Common Stock | 1,489 | $0.00 | - | |
| Third Rock Ventures IV, L.P. | Other | Common Stock | 1,600,000 | - | - | |
| Charles J. Homcy | Gift | Common Stock | 28,423 | $0.00 | - | |
| Herve Hoppenot | Grant or award | Stock Option (Right to Buy) | 36,000 | $0.00 | - | |
| Charles J. Homcy | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Phillips Courtney - Officer | Grant or award | Restricted Stock Units | 22,000 | $0.00 | - | |
| Jason V. Coloma - Officer | Grant or award | Restricted Stock Units | 100,000 | $0.00 | - | |
| Atul Dandekar - Officer | Grant or award | Restricted Stock Units | 25,000 | $0.00 | - | |
| Harold Bernstein - Officer | Grant or award | Restricted Stock Units | 40,000 | $0.00 | - | |
| Amy Bachrodt - Officer | Grant or award | Restricted Stock Units | 22,000 | $0.00 | - | |
| Sekar Kathiresan | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Nancy C. Andrews | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Neil Exter | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Catherine A. Sohn | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
 Jonathan E. Lim | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Daniel K. Spiegelman | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Richard H. Scheller | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Richard H. Scheller | Open-market sale | Common Stock | 20,744 | $22.37 | $464K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Coloma Jason V | Officer | 34,501 | $923K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Maze Therapeutics, Inc. (MAZE) had 18 insider filings in the last 90 days, with the most recent on 2026-08-17. The full record for MAZE runs to 62 Form 4 filings, the earliest from 2025-08-17. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of MAZE were filed in the last 90 days.
21 insider sales of MAZE were filed in the last 90 days, totaling $4.73M.
This page tracks MAZE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add MAZE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
